Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.

Boswell CA, Yadav DB, Mundo EE, Yu SF, Lacap JA, Fourie-O'Donohue A, Kozak KR, Ferl GZ, Zhang C, Ho J, Ulufatu S, Khawli LA, Lin K.

Oncotarget. 2019 Oct 22;10(58):6234-6244. doi: 10.18632/oncotarget.27263. eCollection 2019 Oct 22.

2.

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.

Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA, Phillips GDL.

Mol Cancer Ther. 2018 Jul;17(7):1441-1453. doi: 10.1158/1535-7163.MCT-17-0296. Epub 2018 Apr 25.

3.

Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.

Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC.

Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.

4.

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.

Lewis Phillips GD, Nishimura MC, Lacap JA, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS.

Breast Cancer Res Treat. 2017 Aug;164(3):581-591. doi: 10.1007/s10549-017-4279-4. Epub 2017 May 10.

5.

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K.

Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16.

6.

MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.

Asundi J, Lacap JA, Clark S, Nannini M, Roth L, Polakis P.

Mol Cancer Ther. 2014 Jun;13(6):1599-610. doi: 10.1158/1535-7163.MCT-13-0446. Epub 2014 Mar 20.

7.

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D.

Neoplasia. 2013 Dec;15(12):1314-29.

8.

Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate.

Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, Lin K.

J Nucl Med. 2012 Sep;53(9):1454-61. doi: 10.2967/jnumed.112.103168. Epub 2012 Aug 7.

Supplemental Content

Loading ...
Support Center